These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16985050)
1. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. García-Morales P; Hernando E; Carrasco-García E; Menéndez-Gutierrez MP; Saceda M; Martínez-Lacaci I Mol Cancer Ther; 2006 Sep; 5(9):2172-81. PubMed ID: 16985050 [TBL] [Abstract][Full Text] [Related]
2. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271 [TBL] [Abstract][Full Text] [Related]
3. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396 [TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Pallet N; Thervet E; Le Corre D; Knebelmann B; Nusbaum P; Tomkiewicz C; Meria P; Flinois JP; Beaune P; Legendre C; Anglicheau D Kidney Int; 2005 Jun; 67(6):2422-33. PubMed ID: 15882288 [TBL] [Abstract][Full Text] [Related]
5. Determinants of rapamycin sensitivity in breast cancer cells. Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980 [TBL] [Abstract][Full Text] [Related]
6. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Wang LH; Chan JL; Li W Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506 [TBL] [Abstract][Full Text] [Related]
7. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Kuo PL; Hsu YL; Cho CY Mol Cancer Ther; 2006 Dec; 5(12):3209-21. PubMed ID: 17172425 [TBL] [Abstract][Full Text] [Related]
8. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Basso AD; Solit DB; Munster PN; Rosen N Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Srethapakdi M; Liu F; Tavorath R; Rosen N Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672 [TBL] [Abstract][Full Text] [Related]
10. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Mita MM; Mita A; Rowinsky EK Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096 [TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin: a new molecular target for breast cancer. Mita MM; Mita A; Rowinsky EK Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941 [TBL] [Abstract][Full Text] [Related]
12. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Xu Y; Chen SY; Ross KN; Balk SP Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382 [TBL] [Abstract][Full Text] [Related]
13. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. Feng LX; Ravindranath N; Dym M J Biol Chem; 2000 Aug; 275(33):25572-6. PubMed ID: 10849422 [TBL] [Abstract][Full Text] [Related]
14. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Law M; Forrester E; Chytil A; Corsino P; Green G; Davis B; Rowe T; Law B Cancer Res; 2006 Jan; 66(2):1070-80. PubMed ID: 16424043 [TBL] [Abstract][Full Text] [Related]
17. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc. Benaud CM; Dickson RB Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151 [TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of the immunosuppressant rapamycin. Dumont FJ; Su Q Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303 [TBL] [Abstract][Full Text] [Related]
20. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]